Novartis plans new sales approach for cholesterol lowering drug - WSJ

seekingalpha2021-11-22

In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sales strategy to promote the company’s cholesterol-busting therapy Leqvio, TheWall Street Journal ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Novice2
2021-11-22
Novice2
No update on the vaccine?
Investcub
2021-11-22
Investcub
Happy to see competition is heating up!!!
Chrnox
2021-11-22
Chrnox
[Miser]
- Chrnox:
  [Miser]
Calvinchin
2021-11-22
Calvinchin
👌🏼

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1135443897?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-22 20:29","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1135443897","market":"us","top_or_hot":-1,"title":"Novartis plans new sales approach for cholesterol lowering drug - WSJ","media":"seekingalpha","content":"<div>\n<p>In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sales strategy to promote the company’s cholesterol-busting therapy Leqvio, TheWall Street Journal ...</p>\n\n<a href=\"https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis plans new sales approach for cholesterol lowering drug - WSJ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis plans new sales approach for cholesterol lowering drug - WSJ\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 20:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sales strategy to promote the company’s cholesterol-busting therapy Leqvio, TheWall Street Journal ...</p>\n\n<a href=\"https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVS","symbol_name":"诺华","start_time":0,"source_url":"https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj","article_id":"1135443897","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135443897","pubTimestamp":1637584143,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sale","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVS":"诺华"},"translate_title":"诺华公司计划销售降胆固醇药物的新方法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9},"content_text":"In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sales strategy to promote the company’s cholesterol-busting therapy Leqvio, TheWall Street Journal reports.\nUnlike a promotional strategy reliant on sales representatives, the Swiss pharma giant plans to sell Leqvio targeting 200 hospital systems across the nation.\nThrough the so-called population health approach, the company expects the health care systems through electronic health records to assist it in identifying the patients who could qualify for the drug after failing to control their cholesterol with current therapies.\nFor decades, patients took statins to control the type of cholesterol, low-density lipoprotein, or LDL targeted by Leqvio.\nHowever, the twice-yearly injection is said to be more powerful than statins and competes against Repatha from Amgen(NASDAQ:AMGN)and Praluent from Sanofi(NASDAQ:SNY)and Regeneron(NASDAQ:REGN), two other drugs with a similar mechanism of action to Leqvio.\nWith Repatha and Praluent requiring self-injection every two or four weeks, Novartis (NVS) expects Leqvio will have the edge with twice-yearly dosing.\nIn late 2020, Leqvio, also called inclisiran, was approved in Europe.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":875052053,"gmtCreate":1637591660087,"gmtModify":1637591660181,"author":{"id":"4094948028342190","authorId":"4094948028342190","name":"Novice2","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4094948028342190","authorIdStr":"4094948028342190"},"htmlText":"No update on the vaccine?","listText":"No update on the vaccine?","text":"No update on the vaccine?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875052053","repostId":1135443897,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875060514,"gmtCreate":1637588833510,"gmtModify":1637588855672,"author":{"id":"3584582153384625","authorId":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3584582153384625","authorIdStr":"3584582153384625"},"htmlText":"Happy to see competition is heating up!!!","listText":"Happy to see competition is heating up!!!","text":"Happy to see competition is heating up!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875060514","repostId":1135443897,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875032317,"gmtCreate":1637586050740,"gmtModify":1637586050827,"author":{"id":"3568940418649845","authorId":"3568940418649845","name":"Chrnox","avatar":"https://static.tigerbbs.com/d8298e6f2695e61a0ffe90273947e675","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3568940418649845","authorIdStr":"3568940418649845"},"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875032317","repostId":1135443897,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6679370,"gmtCreate":1637586061791,"gmtModify":1637586061819,"authorId":3568940418649845,"author":{"id":3568940418649845,"idStr":"3568940418649845","authorId":3568940418649845,"name":"Chrnox","avatar":"https://static.tigerbbs.com/d8298e6f2695e61a0ffe90273947e675","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875032317,"type":1,"supId":0,"prevId":0,"content":"[Miser]","text":"[Miser]","html":"[Miser]"}],"langContent":"CN"},{"id":875097392,"gmtCreate":1637585152621,"gmtModify":1637585152793,"author":{"id":"3576278607547570","authorId":"3576278607547570","name":"Calvinchin","avatar":"https://static.tigerbbs.com/f9656b958bb6c4643873a171eebbbc8f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576278607547570","authorIdStr":"3576278607547570"},"htmlText":"👌🏼&nbsp;","listText":"👌🏼&nbsp;","text":"👌🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875097392","repostId":1135443897,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":46,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135443897"}